Clinical Trials on Ultra-high Risk for Psychosis in Switzerland
Total 20 results
-
Rene KahnCompletedUltra High Risk for PsychosisSpain, Austria, Germany, Israel, Italy, Netherlands, Norway, Switzerland, United Kingdom
-
University of ZurichUnknown
-
Brigham and Women's HospitalNational Institute of Mental Health (NIMH); Yale University; OrygenRecruitingPsychosis | Remission | Conversion | Clinical High RiskUnited States, United Kingdom, Canada, Italy, Australia, Chile, China, Denmark, Germany, Hong Kong, Korea, Republic of, Singapore, Spain, Switzerland
-
Array BioPharmaCompletedAML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDSUnited States, Australia, Italy, Spain, France, Switzerland, United Kingdom
-
Insel Gruppe AG, University Hospital BernNot yet recruitingRisk Reduction | Hypobaric Hypoxia | High AltitudeSwitzerland
-
Balgrist University HospitalIndustry (Schülke & Mayr AG, Switzerland and Germany)RecruitingElective Surgery | High Risk | Prevention of Surgical Site Infections | Randomized-controlled TrialSwitzerland
-
University of ZurichKliniken ValensCompletedDisease With a Risk for ChronicitySwitzerland
-
Insel Gruppe AG, University Hospital BernETH ZurichNot yet recruitingPediatric Oncology Patients With Risk for InfectionsSwitzerland
-
Novartis PharmaceuticalsTerminatedMyelofibrosis With High Molecular Risk MutationsBelgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
-
Amsterdam UMCRecruitingBarrett Esophagus | Submucosal Esophageal Adenocarcinoma | High-risk Mucosal Esophageal AdenocarcinomaNetherlands, Belgium, Australia, United Kingdom, Germany, Switzerland
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UnknownBarrett Esophagus | Adenocarcinoma Esophagus | Submucosal Esophageal Adenocarcinoma | High-risk Mucosal Esophageal AdenocarcinomaFrance, United Kingdom, Belgium, Germany, Switzerland, Australia, Netherlands
-
Bristol-Myers SquibbCompletedHigh Risk Stage III MelanomaItaly, Poland, United Kingdom, United States, Netherlands, Spain, Australia, France, Germany, Canada, Russian Federation, Belgium, Norway, Switzerland, Sweden, Finland, Austria, Denmark, Czechia
-
ECRI bvUniversity of Bern; European Cardiovascular Research Center; Terumo Medical Corporation and other collaboratorsCompletedCoronary Artery Disease | PCI | High Bleeding RiskNetherlands, France, United Kingdom, Australia, Singapore, Japan, Italy, Poland, Spain, Switzerland, Israel, Argentina, Austria, Bahrain, Bangladesh, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, India, Korea, Republic... and more
-
Christian BalmerTerminatedSudden Cardiac Death | Wolff-Parkinson-White Syndrome | Risk StratificationSwitzerland
-
Gustave Roussy, Cancer Campus, Grand ParisRecruitingHigh-Risk Neuroblastoma | Patient With Insufficient Response ChemoimmunotherapyFrance, Germany, Israel, Spain, United Kingdom, Belgium, Norway, Sweden, Finland, Australia, Czechia, Italy, Netherlands, Slovenia, Switzerland, Denmark, Greece, Lithuania, Slovakia
-
Ablynx, a Sanofi companyCompletedUnstable Angina | Non ST Segment Elevation Myocardial Infarction (NSTEMI) | Stable Angina (Associated With High Risk PCI)Poland, Belgium, Germany, Israel, Austria, Switzerland, Czechia
-
AmgenTerminatedHigh-risk Diffuse Large B-cell LymphomaUnited States, Italy, Belgium, Switzerland, Australia, France, Greece
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Sweden, Canada, Australia, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, Greece, Japan, Turkey, Netherlands, Romania, China, United Kingdom, Portugal, Italy, France, Slovakia, Austria, Czechi... and more
-
AstraZenecaCompletedPeripheral Arterial Disease (PAD) | Moderate Risk for Cardiovascular Disease (CVD)France, Netherlands, Switzerland, Greece, Belgium, Italy
-
Merck Sharp & Dohme LLCRecruitingHigh-risk Non-muscle Invasive Bladder CancerCanada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Colombia, ... and more